Gilead Sciences, Inc. (GILD) Shares Bought by BlackRock Inc.
BlackRock Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 104,906,494 shares of the biopharmaceutical company’s stock after purchasing an additional 1,937,031 shares during the quarter. BlackRock Inc. owned about 8.03% of Gilead Sciences worth $7,425,281,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Keel Point LLC boosted its holdings in shares of Gilead Sciences by 0.4% in the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the period. West Oak Capital LLC boosted its holdings in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the period. First Heartland Consultants Inc. boosted its holdings in shares of Gilead Sciences by 0.4% in the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares during the period. Arrow Financial Corp boosted its holdings in shares of Gilead Sciences by 0.3% in the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 45 shares during the period. Finally, Westover Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 0.8% in the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after acquiring an additional 46 shares during the period. 76.30% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-bought-by-blackrock-inc/1720984.html.
In other news, EVP Gregg H. Alton sold 50,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 666,819 shares of company stock worth $52,303,086. 1.30% of the stock is owned by corporate insiders.
Several equities research analysts have recently commented on the company. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Thursday, August 31st. Deutsche Bank AG restated a “buy” rating and set a $81.00 price target on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a research note on Friday, October 13th. Credit Suisse Group restated an “outperform” rating and set a $85.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $84.87.
Shares of Gilead Sciences, Inc. (GILD) opened at $72.82 on Thursday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The stock has a market capitalization of $94,717.57, a PE ratio of 7.57, a price-to-earnings-growth ratio of -1.21 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the company earned $2.75 EPS. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. equities analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.